Search Market Research Report
Ataxia Market Size, Share Global Analysis Report, , 2021 – 2026
Ataxia Market By Disease Type (Idiopathic, Acquired Ataxia, and Genetic Ataxia), By Treatment Type (Speech Therapy, Physical Therapy, Pharmacotherapy, and Others), and By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2026
Industry Insights
According to the report published by the Facts and Factors, global demand for the ataxia market was estimated at approximately USD 29,401.1 Million in 2020 and is expected to generate revenue of around USD 46,000.8 Million by the end of 2026, growing at a CAGR of around 10.2% between 2021 and 2026.
Market Overview
Ataxia is a type of group of degenerative neurological diseases, which affects the coordination and movement center of the brain (cerebellum). People with ataxia have trouble in speech, swallowing, and coordination or maintaining balance. In addition, the ataxia has been bifurcated into three types based on the cause: genetic ataxia, acquired ataxia, and idiopathic ataxia. The genetic ataxia is caused due to the damaged gene that leads to ataxia, which is passed from one generation to the other generation. The acquired ataxia is caused due to external factors such as head trauma, vitamin deficiencies, brain tumor, microbial infection, and exposure to alcohol or drugs. The idiopathic ataxia is a kind of condition in which the cause is unidentified.
Ataxia could develop at any age group and is developing in nature; especially, it gets worse with time. Several symptoms related to the ataxia consist of difficulty in walking, a decrease in coordination, and impaired balance with frequent falls, muscle tremors, vision problems, loss of fine motor skills, slurred speech, and others.
Industry Growth Factor
The ataxia market is expected to observe a major growth rate during the forecast period. The increase in cases of ataxia and a constantly improving rate of diagnosis and treatment are key factors driving the growth of the global ataxia market. Another important aspect that is propelling the market growth includes numerous technological developments in pharmacotherapy, offering treatment against the symptoms of ataxia. Moreover, the broad research and development activities with the pipeline drugs are likely to fuel the market growth over the analysis period. Besides, the increasing support from numerous organizations is helping the market size to grow.
On the other hand, the lack of product approval against the ataxia treatment might restrain the market expansion in the upcoming years. Also, the current expiry of a few drugs to give treatment against symptomatic ataxia can limit the market growth. Conversely, the rising count of government initiatives to augment awareness regarding ataxia is bringing lucrative opportunities for the market.
Segmentation Analysis
The global ataxia market has been segmented into disease type, treatment type, and distribution channel. On the basis of the type of disease, the global ataxia market has been classified into idiopathic, acquired ataxia, and genetic ataxia. Based on the type of treatment, the global ataxia market has been categorized into speech therapy, physical therapy, pharmacotherapy, and others. In terms of distribution channels, the global ataxia market has been bifurcated into hospital pharmacies, online pharmacies, and retail pharmacies.
Report Scope
Report Attribute |
Details |
Market Size in 2020 |
USD 29,401.1 Million |
Projected Market Size in 2026 |
USD 46,000.8 Million |
CAGR Growth Rate |
10.2% CAGR |
Base Year |
2020 |
Forecast Years |
2021-2026 |
Key Market Players |
CRISPR Therapeutics, GlaxoSmithKline plc, Capsida Biotherapeutics Inc., Pfizer Inc., Bio-Techne, Acorda Therapeutics, Cellectis SA, Larimar Therapeutics Inc., H. Lundbeck A/S, Sanofi, bluebird bio Inc., Merck & Co. Inc., Editas Medicine, Cellectis SA, Healx, Allergan, and Intellia Therapeutics Inc., among others. |
Key Segment |
By Disease Type, By Treatment Type, By Distribution Channel, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Regional Analysis
On the basis of regional analysis, the ataxia market is segmented into five major regions, namely, North America, Latin America, Asia-Pacific, Europe, and the Middle East, and Africa. In terms of revenue, the North American region is dominating the global ataxia market. The increasing financial support from the government, along with the increasing cases of ataxia, which is contributing to the support organization for the patient diagnosis and treatment, are factors that are expected to contribute significantly to the regional market upsurge.
The Asia-Pacific ataxia market is anticipated to have a significant place in the market during the forecast period. This quick market development in the region is because of key factors like the augmented population with the genetic strains of ataxia and the increase in awareness associated with ataxia. Additionally, the government is also taking programs to cut down the disorders regarding ataxia. This, in turn, will probably stimulate opportunities in the global ataxia market.
Competitive Players
Major companies operating in the global ataxia market include:
- CRISPR Therapeutics
- GlaxoSmithKline plc
- Capsida Biotherapeutics Inc.
- Pfizer Inc.
- Bio-Techne
- Acorda Therapeutics
- Cellectis SA
- Larimar Therapeutics Inc.
- H. Lundbeck A/S
- Sanofi
- bluebird bio Inc.
- Merck & Co. Inc.
- Editas Medicine
- Cellectis SA
- Healx
- Allergan
- Intellia Therapeutics Inc.
In addition, the leading companies driving in the ataxia market are adopting several strategies such as new product launches, collaborations, and product approvals, which in turn, are fuelling the ataxia market expansion across the globe.
Disease Type Segment Analysis
- Idiopathic
- Acquired Ataxia
- Genetic Ataxia
Treatment Type Segment Analysis
- Speech Therapy
- Physical Therapy
- Pharmacotherapy
- Others
Distribution Channel Segment Analysis
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Regional Segment Analysis
- North America
- U.S.
- Canada
- Europe
- U.K.
- France
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- The Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East Africa
Table of Content
Industry Major Market Players
- CRISPR Therapeutics
- GlaxoSmithKline plc
- Capsida Biotherapeutics Inc.
- Pfizer Inc.
- Bio-Techne
- Acorda Therapeutics
- Cellectis SA
- Larimar Therapeutics Inc.
- H. Lundbeck A/S
- Sanofi
- bluebird bio Inc.
- Merck & Co. Inc.
- Editas Medicine
- Cellectis SA
- Healx
- Allergan
- Intellia Therapeutics Inc.
Copyright © 2023 - 2024, All Rights Reserved, Facts and Factors